Trial comparisons

curl "https://conductscience.org/api/comparisons/v1?page=176"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=176

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00705679-b5d874a1",
        "title": "Oral TDF vs Oral Placebo: Number of HIV-1 Infections of Oral TDF and Oral Placebo Arms",
        "summary": "52 of 993 against 35 of 999; risk difference 1.7 points, 95% interval -0.1 to 3.6; NCT00705679, Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women",
        "record": "/library/comparisons/NCT00705679-b5d874a1",
        "nct_id": "NCT00705679",
        "kind": "outcome",
        "participants": 1992,
        "risk_difference": {
          "value": 0.017331530926697092,
          "lower": -0.0007234807305026084,
          "upper": 0.035772807975588086
        },
        "group_1": "52 of 993",
        "group_2": "35 of 999",
        "difference": "1.7 points",
        "interval": "-0.1 to 3.6",
        "trial_title": "Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women"
      },
      {
        "id": "NCT00705679-b5e3e0dc",
        "title": "TFV Gel vs Placebo Gel: Number of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel Arms",
        "summary": "61 of 996 against 70 of 996; risk difference -0.9 points, 95% interval -3.1 to 1.3; NCT00705679, Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women",
        "record": "/library/comparisons/NCT00705679-b5e3e0dc",
        "nct_id": "NCT00705679",
        "kind": "outcome",
        "participants": 1992,
        "risk_difference": {
          "value": -0.009036144578313254,
          "lower": -0.031064545670364253,
          "upper": 0.012893423006770752
        },
        "group_1": "61 of 996",
        "group_2": "70 of 996",
        "difference": "-0.9 points",
        "interval": "-3.1 to 1.3",
        "trial_title": "Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=177",
  "request_id": "dSt5_JUHAeYb42CJ"
}